The FDA granted accelerated approval to the RAS GTPase inhibitor sotorasib (Lumakras, Amgen) for the treatment of adults with KRAS G12C-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.
This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for approximately 25% of mutations in NSCLC. KRAS G12C mutations represent approximately 13%